Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: a study on behalf of the EBMT and the GoCART coalition
Patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary central nervous system (CNS) lymphoma (SCNSL) face a dismal prognosis. They have been excluded from most clinical CAR T-cell trials as investigators feared an increased risk for severe immun...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 May 2025
|
| In: |
HemaSphere
Year: 2025, Volume: 9, Issue: 5, Pages: 1-11 |
| ISSN: | 2572-9241 |
| DOI: | 10.1002/hem3.70146 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hem3.70146 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/hem3.70146 
|
| Author Notes: | Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, Michael Daskalakis, Marc Wehrli, David Beauvais, Jürgen Finke, Elisabeth Schorb, Peter Vandenberghe, Philipp Berning, Matthias Stelljes, Francis Ayuk, Ron Ram, Malte Von Bonin, Peter Dreger, Wolfgang Bethge, Andrea Kuhnl, Lasse Jost, Friedrich Stölzel, Bastian von Tresckow, Christoph Renner, Stephan Fuhrmann, Jacques-Emmanuelle Galimard, Eva Michel, Ali Bazarbachi, Anna Sureda Balari, Norbert Schmitz, Bertram Glass |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1941618421 | ||
| 003 | DE-627 | ||
| 005 | 20251119165845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251119s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hem3.70146 |2 doi | |
| 035 | |a (DE-627)1941618421 | ||
| 035 | |a (DE-599)KXP1941618421 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ossami Saidy, Anna |d 1990- |e VerfasserIn |0 (DE-588)1109905017 |0 (DE-627)864489714 |0 (DE-576)475648110 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma |b a study on behalf of the EBMT and the GoCART coalition |c Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, Michael Daskalakis, Marc Wehrli, David Beauvais, Jürgen Finke, Elisabeth Schorb, Peter Vandenberghe, Philipp Berning, Matthias Stelljes, Francis Ayuk, Ron Ram, Malte Von Bonin, Peter Dreger, Wolfgang Bethge, Andrea Kuhnl, Lasse Jost, Friedrich Stölzel, Bastian von Tresckow, Christoph Renner, Stephan Fuhrmann, Jacques-Emmanuelle Galimard, Eva Michel, Ali Bazarbachi, Anna Sureda Balari, Norbert Schmitz, Bertram Glass |
| 264 | 1 | |c 21 May 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.11.2025 | ||
| 520 | |a Patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary central nervous system (CNS) lymphoma (SCNSL) face a dismal prognosis. They have been excluded from most clinical CAR T-cell trials as investigators feared an increased risk for severe immune effector cell-associated neurotoxicity (ICANS). To investigate the potential of anti-CD19 CAR T-cell therapy (CART) in such patients, we analyzed data of 100 patients with CNS manifestation treated with CART between January 2018 and July 2023 and reported to European Society for Blood and Marrow Transplantation. Median age was 62 years. Of patients, 58% had failed ≥3 treatment lines, and 40% had received autologous stem-cell transplantation before CART. Fifty-nine patients received axicabtagene ciloleucel, 38 patients were treated with tisagenlecleucel, three patients received other products. At the time of CART, 67 patients had active CNS disease. Overall and progression-free survival (PFS) at 24 months were 37% and 28%. Relapse incidence (RI) at 24 months was 59%, whereas non-relapse mortality at 1 year was 7%. Cytokine release syndrome (CRS) and ICANS of any grade occurred in 83% and 42% of patients, respectively. CRS grade 3 occurred in 11 and ICANS grades 3-4 in 17 patients. Two patients died of neurotoxicity. Elevated lactate dehydrogenase was an independent risk factor for RI and PFS (hazard ratio [HR] 2.4, p = 0.003; HR: 1.9, p = 0.016). Patients with ECOG 2-3 had a significantly increased risk for the development of ICANS (HR 2.68, p = 0.002). These data support the implementation of CART as treatment for patients with r/r PCNSL and SCNSL. | ||
| 700 | 1 | |a Peczynski, Christophe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thieblemont, Catherine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Daskalakis, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wehrli, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beauvais, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finke, Jürgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schorb, Elisabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vandenberghe, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berning, Philipp |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stelljes, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ayuk, Francis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ram, Ron |e VerfasserIn |4 aut | |
| 700 | 1 | |a Von Bonin, Malte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Bethge, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuhnl, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jost, Lasse |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stölzel, Friedrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Tresckow, Bastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Renner, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fuhrmann, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Galimard, Jacques-Emmanuelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michel, Eva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bazarbachi, Ali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balari, Anna Sureda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glass, Bertram |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d Hoboken : John Wiley & Sons Ltd., 2017 |g 9(2025), 5, Artikel-ID e70146, Seite 1-11 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnas |a Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma a study on behalf of the EBMT and the GoCART coalition |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:5 |g elocationid:e70146 |g pages:1-11 |g extent:11 |a Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma a study on behalf of the EBMT and the GoCART coalition |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hem3.70146 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hem3.70146 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251119 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 999 | |a KXP-PPN1941618421 |e 4808834073 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Anna Ossami Saidy, Christophe Peczynski, Catherine Thieblemont, Michael Daskalakis, Marc Wehrli, David Beauvais, Jürgen Finke, Elisabeth Schorb, Peter Vandenberghe, Philipp Berning, Matthias Stelljes, Francis Ayuk, Ron Ram, Malte Von Bonin, Peter Dreger, Wolfgang Bethge, Andrea Kuhnl, Lasse Jost, Friedrich Stölzel, Bastian von Tresckow, Christoph Renner, Stephan Fuhrmann, Jacques-Emmanuelle Galimard, Eva Michel, Ali Bazarbachi, Anna Sureda Balari, Norbert Schmitz, Bertram Glass"]},"person":[{"role":"aut","given":"Anna","display":"Ossami Saidy, Anna","family":"Ossami Saidy"},{"family":"Peczynski","role":"aut","given":"Christophe","display":"Peczynski, Christophe"},{"family":"Thieblemont","display":"Thieblemont, Catherine","given":"Catherine","role":"aut"},{"role":"aut","given":"Michael","display":"Daskalakis, Michael","family":"Daskalakis"},{"family":"Wehrli","display":"Wehrli, Marc","role":"aut","given":"Marc"},{"role":"aut","given":"David","display":"Beauvais, David","family":"Beauvais"},{"family":"Finke","role":"aut","given":"Jürgen","display":"Finke, Jürgen"},{"family":"Schorb","display":"Schorb, Elisabeth","given":"Elisabeth","role":"aut"},{"role":"aut","given":"Peter","display":"Vandenberghe, Peter","family":"Vandenberghe"},{"family":"Berning","display":"Berning, Philipp","role":"aut","given":"Philipp"},{"family":"Stelljes","display":"Stelljes, Matthias","role":"aut","given":"Matthias"},{"display":"Ayuk, Francis","given":"Francis","role":"aut","family":"Ayuk"},{"family":"Ram","display":"Ram, Ron","role":"aut","given":"Ron"},{"given":"Malte","role":"aut","display":"Von Bonin, Malte","family":"Von Bonin"},{"role":"aut","given":"Peter","display":"Dreger, Peter","family":"Dreger"},{"family":"Bethge","display":"Bethge, Wolfgang","role":"aut","given":"Wolfgang"},{"display":"Kuhnl, Andrea","given":"Andrea","role":"aut","family":"Kuhnl"},{"given":"Lasse","role":"aut","display":"Jost, Lasse","family":"Jost"},{"family":"Stölzel","display":"Stölzel, Friedrich","given":"Friedrich","role":"aut"},{"role":"aut","given":"Bastian","display":"von Tresckow, Bastian","family":"von Tresckow"},{"given":"Christoph","role":"aut","display":"Renner, Christoph","family":"Renner"},{"family":"Fuhrmann","given":"Stephan","role":"aut","display":"Fuhrmann, Stephan"},{"family":"Galimard","display":"Galimard, Jacques-Emmanuelle","given":"Jacques-Emmanuelle","role":"aut"},{"family":"Michel","display":"Michel, Eva","role":"aut","given":"Eva"},{"given":"Ali","role":"aut","display":"Bazarbachi, Ali","family":"Bazarbachi"},{"display":"Balari, Anna Sureda","role":"aut","given":"Anna Sureda","family":"Balari"},{"family":"Schmitz","given":"Norbert","role":"aut","display":"Schmitz, Norbert"},{"family":"Glass","role":"aut","given":"Bertram","display":"Glass, Bertram"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1941618421","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"21 May 2025"}],"note":["Gesehen am 19.11.2025"],"relHost":[{"id":{"eki":["1015324924"],"issn":["2572-9241"],"zdb":["2922183-3"]},"disp":"Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma a study on behalf of the EBMT and the GoCART coalitionHemaSphere","physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"role":"isb","display":"European Hematology Association"}],"note":["Gesehen am 18.01.2024"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Hoboken ; [Philadelphia, Pennsylvania]","dateIssuedDisp":"2024-","publisher":"John Wiley & Sons Ltd. ; Wolters Kluwer Health","dateIssuedKey":"2024"}],"recId":"1015324924","pubHistory":["Volume 1, issue 1 (December 2017)-"],"title":[{"title":"HemaSphere","subtitle":"open access journal of the European Hematology Association","title_sort":"HemaSphere"}],"language":["eng"],"part":{"pages":"1-11","extent":"11","issue":"5","year":"2025","text":"9(2025), 5, Artikel-ID e70146, Seite 1-11","volume":"9"}}],"id":{"doi":["10.1002/hem3.70146"],"eki":["1941618421"]},"physDesc":[{"noteIll":"Illustrationen","extent":"11 S."}],"language":["eng"],"title":[{"title_sort":"Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma","title":"Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma","subtitle":"a study on behalf of the EBMT and the GoCART coalition"}]} | ||
| SRT | |a OSSAMISAIDEFFICACYAN2120 | ||